Ajooni Biotech has scheduled its 16th Annual General Meeting (AGM) for July 29, 2026, to be held through video conferencing. The meeting will transact ordinary business, including the adoption of audited financial statements for the year ended March 31, 2026, and the re-appointment of Director Gursimran Singh. Shareholders will also vote on special resolutions to increase the company's authorised share capital and issue equity shares on a preferential basis to a promoter.

The Board proposes to increase the authorised share capital from ₹50 crore to ₹70 crore by creating an additional 10 crore equity shares of ₹2 each. Additionally, the company seeks approval to allot up to 90,00,000 equity shares to Healthy Biosciences Limited, a promoter, at a price of ₹4.30 per share, including a premium of ₹2.30. The issue aims to raise ₹3.87 crore, primarily for constructing storage godowns and general corporate purposes.

Key AGM Dates

The register of members and share transfer books will remain closed from July 23, 2026, to July 29, 2026, to determine shareholder eligibility. The cut-off date for ascertaining eligibility for remote e-voting and polling is July 17, 2026. National Securities Depositories Limited (NSDL) will provide the remote e-voting facility.

Proposed Preferential Allotment Details

The preferential allotment is subject to the approval of shareholders by way of a special resolution. The relevant date for determining the minimum issue price is June 29, 2026. The company intends to complete the allotment within 15 days of receiving necessary approvals.

Ajooni Biotech has closed its trading window for all officers and designated employees, including directors, effective from Wednesday, July 01, 2026. The closure is implemented to ensure compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as the company prepares to declare its unaudited financial results for the quarter ended June 30, 2026. The restriction prevents insider trading during the sensitive period surrounding financial disclosures.

The decision aligns with the company's code of conduct for the prohibition of insider trading and Circular No. NSE/CML/2019/11 dated April 02, 2019. The trading window will remain closed for all designated personnel until 48 hours after the unaudited financial results for the quarter ended June 30, 2026 are officially announced to the stock exchange. Both the start date and the end date of the closure are inclusive.

Compliance and Regulatory Framework

The closure of the trading window is a standard regulatory procedure mandated by SEBI to maintain market integrity and prevent the misuse of unpublished price-sensitive information (UPSI). By adhering to these regulations, Ajooni Biotech ensures that all market participants have equal access to material information at the time of public disclosure.

The intimation was formally addressed to the National Stock Exchange of India Ltd, confirming the company's adherence to the prescribed timelines and protocols. The communication was authenticated by Swati Vijan, Company Secretary of Ajooni Biotech Limited.